132 related articles for article (PubMed ID: 2290216)
1. [Effect of biliary obstruction and cholangitis on serum SPan-1 level].
Matsumoto S; Muranaka T; Hanada K; Matsuura Y; Oshiumi Y
Kaku Igaku; 1990 Dec; 27(12):1443-6. PubMed ID: 2290216
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
3. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas.
Nanashima A; Yamaguchi H; Nakagoe T; Matsuo S; Sumida Y; Tsuji T; Sawai T; Yamaguchi E; Yasutake T; Ayabe H
J Hepatobiliary Pancreat Surg; 1999; 6(4):391-5. PubMed ID: 10664288
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
5. [Effect of biliary tract obstruction and cholangitis on serum CA 19-9 levels].
Okaga M; Karasawa H; Kobayashi T; Satsukime N; Miki R
Nihon Shokakibyo Gakkai Zasshi; 1985 May; 82(5):1418. PubMed ID: 3861895
[No Abstract] [Full Text] [Related]
6. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer.
Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M
Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269
[TBL] [Abstract][Full Text] [Related]
7. [Basic and clinical studies on SPan-1 RIABEAD kit: usefulness in patients with pancreatic and biliary tract cancer].
Watanabe Y; Endo K; Nakajima K; Hattori N; Sakahara H; Saga T; Nakai T; Hosono M; Yao ZS; Baba N
Kaku Igaku; 1989 Dec; 26(12):1559-65. PubMed ID: 2622087
[No Abstract] [Full Text] [Related]
8. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of tumor marker CA19-9 in acute cholangitis.
Albert MB; Steinberg WM; Henry JP
Dig Dis Sci; 1988 Oct; 33(10):1223-5. PubMed ID: 3168694
[TBL] [Abstract][Full Text] [Related]
11. Biliary obstruction induces extremely elevated serum CA 19-9 levels: case report.
Onal C; Colakoglu T; Ulusan SN; Yapar AF; Kayaselcuk F
Onkologie; 2012; 35(12):780-2. PubMed ID: 23207625
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 assay in patients with extrahepatic cholestatic jaundice.
Barone D; Onetto M; Conio M; Paganuzzi M; Saccomanno S; Aste H; Pugliese V
Int J Biol Markers; 1988; 3(2):95-100. PubMed ID: 3243982
[TBL] [Abstract][Full Text] [Related]
13. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.
Laurent-Puig P; Lubin R; Semhoun-Ducloux S; Pelletier G; Fourre C; Ducreux M; Briantais MJ; Buffet C; Soussi T
Gut; 1995 Mar; 36(3):455-8. PubMed ID: 7698709
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
16. Cholangitis due to malignant obstruction of biliary outflow.
O'Connor MJ; Schwartz ML; McQuarrie DG; Sumner HW
Ann Surg; 1981 Mar; 193(3):341-5. PubMed ID: 7212795
[TBL] [Abstract][Full Text] [Related]
17. A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer.
Satake K; Chung YS; Yokomatsu H; Nakata B; Tanaka H; Sawada T; Nishiwaki H; Umeyama K
Int J Pancreatol; 1990; 7(1-3):25-36. PubMed ID: 2081926
[TBL] [Abstract][Full Text] [Related]
18. [Biochemical markers in the neoplasms of the liver, biliary tract and pancreas].
Higashino K; Sumikawa K
Nihon Rinsho; 1982; 40(1):43-50. PubMed ID: 6177881
[No Abstract] [Full Text] [Related]
19. Evaluation of surgical risk in preoperative biliary drainage patients by blood chemistry laboratory data--with special reference to rate of reduction of serum bilirubin levels.
Nakayama T; Tamae T; Kinoshita H; Okuda K; Imayama Y; Saitoh N; Shibata J; Aoki E; Hasuda A; Saitsu H
Hepatogastroenterology; 1995; 42(4):338-42. PubMed ID: 8586364
[TBL] [Abstract][Full Text] [Related]
20. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
